ArticleFrontiers in cellular and infection microbiology2019
Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant
Article in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Rapid Adaptive Evolution under Combination Therapy inACS infectious diseases · 2026Article
- Antimicrobial resistance analysis of Escherichia coli isolated from foxes in China.Veterinary research communications · 2026Article
- In Vitro Evaluation of Colistin-Meropenem Activity Against XDR and PDR Carbapenemase-ProducingPathogens (Basel, Switzerland) · 2026Article
- A Tentative Clinical Study: Colistin Combined with Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Gram-Negative Bacilli Infection.Infection and drug resistance · 2025Article
- A challenging case of carbapenem resistant Klebsiella pneumoniae-related pyogenic liver abscess with capsular polysaccharide hyperproduction: a case report.BMC infectious diseases · 2024Article
- Synergistic action of 6-gingerol as an adjuvant to colistin for susceptibility enhancement in multidrug-resistantRSC advances · 2024Article
- Mechanism for transmission and pathogenesis of carbapenem-resistant Enterobacterales harboring the carbapenemase IMP and clinical countermeasures.Microbiology spectrum · 2024Article
- Effectiveness of antimicrobial agent combinations against carbapenem-producingFrontiers in microbiology · 2024Article
- Combating antimicrobial resistance: the silent war.Frontiers in pharmacology · 2024Review
- In Vitro antibiotic combinations of Colistin, Meropenem, Amikacin, and Amoxicillin/clavulanate against multidrug-resistant Klebsiella pneumonia isolated from patients with ventilator-associated pneumonia.BMC microbiology · 2023Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Aminoglycosides for the Treatment of Severe Infection Due to Resistant Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2023Review
- Outbreak report of polymyxin-carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes.Scientific reports · 2023Article
- Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics.Antibiotics (Basel, Switzerland) · 2022Review
- Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.Infection and drug resistance · 2022Review
- Prevalence of Carbapenem-ResistantInfection and drug resistance · 2022Article
- Article
- Comparison of Bleeding Risk Between Colistin-Tigecycline and Colistin-Carbapenem Treatment Regimens: A Retrospective Cohort Study.Infection and drug resistance · 2021Article
- Emergence of the Coexistence ofInfection and drug resistance · 2021Article
- In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.Antimicrobial resistance and infection control · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to investigate the synergistic and bactericidal effects of combinations of colistin with meropenem or amikacin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.